Viatris - Company Profile
Save hours of research with our analyst-prepared profile on Viatris. Get financials, SWOT, and competitor insights in one place—your competitors might already have it.
Financial Analysis and Report
Viatris is a global healthcare company dedicated to empowering people worldwide to live healthier at every stage of life. Formed through the merger of Mylan and Upjohn, Viatris combines a rich portfolio of medicines that span various therapeutic areas with a commitment to access and sustainability.
Visual Insights
Viatris Revenue Growth
Viatris Market Distribution
Request the full company profile on Viatris and save hours of research with ready-to-use insights.
About Viatris
Viatris aims to provide access to high-quality medicines while addressing the healthcare needs across the globe, ensuring that essential medications are available to those who need them.
| Aspect | Details |
|---|---|
| Founded | 2020 |
| Headquarters | Canonsburg, Pennsylvania, USA |
| Global Reach | Over 165 countries and territories |
| Employees | Approx. 45,000 |
| Key Focus Areas | Access to medicines, sustainability, innovation |
Leadership Team
The leadership team at Viatris brings a wealth of experience and a shared vision of creating better health and access to medicines around the world.
| Name | Position |
|---|---|
| Scott A. D. Kahn | CEO |
| Rick Gonzalez | Chairman |
| Kurt A. M. M. H. L. Voorn | CFO |
| Sophie A. de Saram | Chief Commercial Officer |
Core Business Segments
Viatris operates in several key therapeutic areas, striving to make healthcare more accessible and affordable through a diverse portfolio.
| Segment | Description |
|---|---|
| Generic Pharmaceuticals | Manufacturing and distribution of generic drugs. |
| Specialty Medicines | Focusing on complex and high-cost therapies. |
| Over-the-Counter Products | Providing accessible healthcare solutions. |
| Biosimilars | Development and marketing of biosimilars to increase access. |
Financial Highlights
Viatris's financial performance reflects its commitment to innovation, access, and sustainability, highlighting the effectiveness of its business model.
| Metric | Value |
|---|---|
| Revenue (2022) | $18 billion |
| Net Income (2022) | $3 billion |
| Market Capitalization | $25 billion |
| R&D Investment | 10% of revenue |
Competitive Landscape
Viatris competes with several key players in the pharmaceutical industry, focusing on delivering quality and access across its product lines.
| Competitor | Focus |
|---|---|
| Teva Pharmaceuticals | Generic pharmaceuticals |
| Sandoz | Biosimilars and generics |
| Amgen | Innovative biopharmaceuticals |
| AbbVie | Specialty and biologic therapies |
Get a Detailed Financial Analysis of Viatris
- ✔ Access Viatris’s revenue, profitability, and growth metrics.
- ✔ Benchmark financials against key competitors.
- ✔ Forecast future performance with reliable market models.
- ✔ Make informed investment and strategic decisions.